Melinta Therapeutics secured a BARDA deal worth nearly $142 million to make two currently approved antibiotics available for children. The deal comes roughly three years after Deerfield Management acquired the antibiotics company and tapped CEO Christine Ann Miller to restructure it. Despite the rising threat of antimicrobial resistance (AMR), Big Pharma has largely retreated from the high-risk field where many antibiotics fail in development while others languish due to a lack of available funding. The ones that do get approved are used sparingly to preserve efficacy and slow further resistance.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters